E5 Murine Monoclonal Antiendotoxin Antibody in Gram-Negative Sepsis: A Randomized Controlled Trial

Article Abstract:

A monoclonal antibody that blocks a bacterial toxin called endotoxin does not lower mortality rates in patients with severe gram-negative sepsis. Gram-negative sepsis is serious bacterial infection that affects many body systems and can cause death. Many of the symptoms are believed to be caused by endotoxin. However, in a study of over 1,000 sepsis patients who received a monoclonal antibody to endotoxin or a placebo, death rates were similar in both groups.

Health aspects, Care and treatment, Monoclonal antibodies

---

Unraveling severe sepsis: why did OPTIMIST fail and what's next?

Article Abstract:

A study of a recombinant form of a natural anticoagulant published in 2003 will probably be the last study of anticoagulants for treating sepsis. The only possible exception is heparin. All other anticoagulants that have been tested have not substantially lowered mortality rates in patients with sepsis. Sepsis is a serious bacterial infection of the blood that can cause multiple organ failure and death.

Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Anticoagulant Preparations, Evaluation, Anticoagulants (Medicine), Anticoagulants, Bacterial infections, Sepsis

---

Continuing Challenges of Sepsis Research

Article Abstract:

Additional research may be needed to determine if antithrombin III treatment benefits some patients with septic shock or septicemia. Both conditions are caused by a serious bacterial infection in the bloodstream that eventually causes multiple organ failure. Antithrombin III treatment is used to prevent abnormal blood clotting.

Septicemia

Similar abstracts:

• Abstracts: Geriatric medicine. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial
• Abstracts: Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels: a randomized, placebo-controlled trial
• Abstracts: Memantine in moderate-to-severe Alzheimer's disease. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
• Abstracts: Treatment regimens in preventive and restorative dentistry. Amalgam at the new millennium. Three restorative materials and topical fluoride gel used in xerostomic patients: a clinical comparison
• Abstracts: Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.